Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis-Reference-Cited by-同舟云学术

Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis

Published:2017-12-04 Issue:4 Volume:47 Page:454-465
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Bonovas S.¹²^ORCID,Lytras T.³,Nikolopoulos G.⁴,Peyrin-Biroulet L.⁵^ORCID,Danese S.¹²^ORCID

Affiliation:

1. Department of Biomedical Sciences; Humanitas University; Milan Italy

2. Department of Gastroenterology; IBD Center; Humanitas Clinical and Research Center; Milan Italy

3. Hellenic Center for Disease Control and Prevention; Athens Greece

4. Medical School; University of Cyprus; Nicosia Cyprus

5. Department of Hepato-Gastroenterology and Inserm U954; University Hospital of Nancy; University of Lorraine; Vandoeuvre-lès-Nancy France

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14449/fullpdf

Reference49 articles.

1. Ulcerative colitis;Ungaro;Lancet,2017

2. Ulcerative colitis;Danese;N Engl J Med,2011

3. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review;Molodecky;Gastroenterology,2012

4. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target;Peyrin-Biroulet;Am J Gastroenterol,2015

5. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management;Harbord;J Crohns Colitis,2017

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome;Journal of Ethnopharmacology;2024-12

2. Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis;Cureus;2024-06-02

3. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2);Zeitschrift für Gastroenterologie;2024-05

4. Microbiota therapeutics for inflammatory bowel disease: the way forward;The Lancet Gastroenterology & Hepatology;2024-05

5. A practical guide to selecting and using new ulcerative colitis therapies;Current Opinion in Gastroenterology;2024-04-11